Slow Capital Inc. Has $5.89 Million Stake in Repligen Corporation $RGEN

Slow Capital Inc. lifted its position in shares of Repligen Corporation (NASDAQ:RGEN) by 23.9% during the third quarter, Holdings Channel.com reports. The firm owned 44,076 shares of the biotechnology company’s stock after buying an additional 8,511 shares during the quarter. Slow Capital Inc.’s holdings in Repligen were worth $5,892,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in RGEN. AQR Capital Management LLC acquired a new stake in shares of Repligen during the first quarter worth $262,000. Jones Financial Companies Lllp increased its position in Repligen by 3,850.6% during the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock worth $814,000 after acquiring an additional 6,238 shares during the period. Goldman Sachs Group Inc. raised its stake in Repligen by 16.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock worth $18,067,000 after purchasing an additional 20,375 shares in the last quarter. Park Avenue Securities LLC bought a new stake in Repligen in the 2nd quarter valued at about $340,000. Finally, Congress Asset Management Co. grew its position in shares of Repligen by 18.0% during the 2nd quarter. Congress Asset Management Co. now owns 152,450 shares of the biotechnology company’s stock worth $18,962,000 after purchasing an additional 23,231 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Insider Activity at Repligen

In related news, COO James Bylund sold 2,191 shares of the stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total value of $331,301.11. Following the completion of the transaction, the chief operating officer owned 21,520 shares of the company’s stock, valued at $3,254,039.20. This represents a 9.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Anthony Hunt sold 20,000 shares of the business’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $154.61, for a total transaction of $3,092,200.00. Following the sale, the director directly owned 80,743 shares in the company, valued at approximately $12,483,675.23. The trade was a 19.85% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 49,657 shares of company stock valued at $7,721,077. 1.20% of the stock is owned by insiders.

Analyst Ratings Changes

RGEN has been the subject of a number of analyst reports. Barclays lifted their price target on shares of Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Evercore ISI raised their price objective on Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Weiss Ratings raised Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, January 12th. Hsbc Global Res raised Repligen to a “strong-buy” rating in a report on Wednesday, October 1st. Finally, HSBC started coverage on Repligen in a research note on Wednesday, October 1st. They issued a “buy” rating and a $150.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $179.62.

Repligen Price Performance

Repligen stock opened at $162.02 on Tuesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $182.52. The stock has a market capitalization of $9.12 billion, a P/E ratio of 8,105.05, a price-to-earnings-growth ratio of 2.94 and a beta of 1.12. The stock has a fifty day moving average of $163.01 and a 200-day moving average of $141.97.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.04. The business had revenue of $188.81 million for the quarter, compared to analyst estimates of $181.23 million. Repligen had a return on equity of 4.66% and a net margin of 0.25%.Repligen’s revenue was up 21.9% compared to the same quarter last year. During the same period last year, the firm posted $0.43 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, sell-side analysts expect that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.